Table 2

Crude risks for clinical events according to the baseline BNP values

Number of patients with eventUnadjusted
(Cumulative 5-year incidence)HR (95% CI)P values
All-cause death
 Group 140 (23.2%)1 (reference)
 Group 231 (39.5%)2.00 (1.24 to 3.19)0.005
 Group 322 (68.3%)3.46 (2.02 to 5.77)<0.001
 Group 426 (56.1%)4.37 (2.62 to 7.16)<0.001
Cardiovascular death
 Group 114 (8.0%)1 (reference)
 Group 215 (22.9%)2.88 (1.38 to 6.05)0.005
 Group 312 (44.2%)5.54 (2.51 to 12.04)<0.001
 Group 417 (42.1%)8.70 (4.24 to 18.15)<0.001
Aortic valve-related death
 Group 110 (6.4%)1 (reference)
 Group 210 (18.1%)2.72 (1.11 to 6.65)0.03
 Group 37 (28.7%)4.70 (1.70 to 12.32)0.004
 Group 49 (26.5%)6.92 (2.72 to 17.40)<0.001
Sudden death
 Group 16 (3.5%)1 (reference)
 Group 24 (4.7%)1.85 (0.47 to 6.53)0.36
 Group 31 (8.3%)1.20 (0.06 to 7.09)0.87
 Group 44 (12.1%)5.17 (1.29 to 18.80)0.02
HF hospitalisation
 Group 119 (9.5%)1 (reference)
 Group 216 (25.7%)2.43 (1.23 to 4.74)0.01
 Group 314 (46.3%)5.59 (2.73 to 11.17)<0.001
 Group 414 (38.3%)5.98 (42.92 to 11.96)<0.001
  • Number of patients with event was counted through the entire follow-up period, while the cumulative incidence was estimated at 5 year. Aortic valve-related death included aortic procedure-related death, sudden death and death due to heart failure. HF hospitalisation was defined as hospitalisation due to worsening heart failure requiring intravenous drug therapy.

  • BNP, B-type natriuretic peptide; HF, heart failure.